Or maybe Schedule 3.. in the 2022 Annual report they dropped the wording 'conducting medical trials' and said ' are preparing dossier'. In the 2023 Half yearly, they didn't mention anything about the S3 activities which is the first time they dropped it off a report since the down scheduling occurred.
The class 5 trademark is for a medicine, if it was for clinics, it, etc it would have been registered under more classes. Also I doubt they would be bringing out another S4 product as the market is saturated and revenue/margins are low.
Or maybe Schedule 3.. in the 2022 Annual report they dropped the...
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add VIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.3¢ |
Change
-0.005(5.10%) |
Mkt cap ! $53.55M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.2¢ | $89.49K | 912.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34999 | 9.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 58242 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| VIT (ASX) Chart |